• Explore /
  • Poster
  • / BXCL701: First-in-class oral activator of systemic innate immunity combined with pembrolizumab, in patients with metastatic castration-resistant prostate cancer (mCRPC) of adenocarcinoma phenotype—Phase 2a results.

BXCL701: First-in-class oral activator of systemic innate immunity combined with pembrolizumab, in patients with metastatic castration-resistant prostate cancer (mCRPC) of adenocarcinoma phenotype—Phase 2a results.

Abstract Poster

Authors

null

Jingsong Zhang

Moffitt Cancer Center, Tampa, FL

Jingsong Zhang , Rahul Raj Aggarwal , Scott T. Tagawa , Mark David Linch , Daniel P. Petrylak , Dan Costin , Johann S. De Bono , Robert Jones , Lawrence Ivan Karsh , Xinhua Zhu , Pascal Borderies , Rashmi Majali Deshpande , Vincent O'Neill , Paul Monk III

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Prostate Cancer

Track

Prostate Cancer - Advanced,Prostate Cancer - Localized

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT03910660

Citation

J Clin Oncol 40, 2022 (suppl 6; abstr 125)

DOI

10.1200/JCO.2022.40.6_suppl.125

Abstract #

125

Poster Bd #

P6

Abstract Disclosures

Similar Posters

First Author: Scott T. Tagawa

First Author: Rahul Raj Aggarwal

First Author: Rahul Raj Aggarwal

First Author: Gero Kramer